Revascularization and bone remodeling of frozen allografts stimulated by intramedullary sustained delivery of FGF-2 and VEGF

Journal of Orthopaedic Research

Volumn 29, Issue 9, 2011, Pages 1431-1436

  Willems, Wouter F ^a   Larsen, Mikko ^b   Giusti, Guilherme ^a   Friedrich, Patricia F ^a   Bishop, Allen T ^a  

^a Department of Orthopedic Surgery   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

allograft; angiogenesis; FGF 2; osteogenesis; VEGF

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; MICROSPHERE; PHOSPHATE BUFFERED SALINE; TACROLIMUS; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOVENOUS SHUNT; ARTICLE; BONE ALLOGRAFT; BONE BLOOD FLOW; BONE REMODELING; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HISTOLOGY; HLA MATCHING; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT; REVASCULARIZATION; SAPHENOUS VEIN GRAFT;

ANIMALS; BONE REGENERATION; BONE TRANSPLANTATION; CRYOPRESERVATION; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; FEMUR; FIBROBLAST GROWTH FACTOR 2; MICROSPHERES; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960246561     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21338     Document Type: Article

References (42)

1. Muscolo DL, Ayerza MA, Aponte-Tinao LA,. 2006. Massive allograft use in orthopedic oncology. Orthop Clin North Am 37 (1): 65-74. (Pubitemid 41719087)
2. Tomford WW,. 2000. Bone allografts: past, present and future. Cell Tissue Bank 1 (2): 105-109.
3. Stevenson S, Emery SE, Goldberg VM,. 1996. Factors affecting bone graft incorporation. Clin Orthop Relat Res 324: 66-74. (Pubitemid 26071752)
4. Beaupied H, Dupuis A, Arlettaz A, et al. 2006. The mode of bone conservation does not affect the architecture and the tensile properties of rat femurs. Biomed Mater Eng 16 (4): 253-259. (Pubitemid 44285884)
5. Dwight TD,. 1999. Biomechanical, issues in bone transplantation. Orthop Clin N Am 30 (4): 553-563.
6. Delloye C, Cornu O, Druez V, et al. 2007. Bone allografts: what they can offer and what they cannot. J Bone Joint Surg Br 89 (5): 574-579. (Pubitemid 46958761)
7. Enneking WF, Mindell ER,. 1991. Observations on massive retrieved human allografts. J Bone Joint Surg Am 73 (8): 1123-1142.
8. Fox EJ, Hau MA, Gebhardt MC, et al. 2002. Long-term followup of proximal femoral allografts. Clin Orthop Relat Res 397: 106-113. (Pubitemid 34442022)
9. Basmanav F, Kose GT, Hasirci V,. 2008. Sequential growth factor delivery from complexed microspheres for bone tissue engineering. Biomaterials 29 (31): 4195-4204.
10. Marie PJ,. 2003. Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 16 (316): 23-32. (Pubitemid 37258340)
11. Dai J, Rabie AB,. 2007. VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res 86 (10): 937-950.
12. Street J, Bao M, deGuzman L, et al. 2002. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99 (15): 9656-9661. (Pubitemid 34831103)
13. Huang Z, Nelson ER, Smith RL, et al. 2007. The sequential expression profiles of growth factors from osteroprogenitors to osteoblasts in vitro. Tissue Eng 13 (9): 2311-2320. (Pubitemid 47404446)
14. Clarkin CE, Emery RJ, Pitsillides AA, et al. 2008. Evaluation of VEGF-mediated signaling in primary human cells reveals a paracrine action for VEGF in osteoblast-mediated crosstalk to endothelial cells. J Cell Physiol 214 (2): 537-544. (Pubitemid 350309010)
15. Asahara T, Bauters C, Zheng L,. 1995. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92 (9 Suppl): 365-371.
16. Wang JS, Aspenberg P,. 1996. Basic fibroblast growth factor enhances bone-graft incorporation: dose and time dependence in rats. J Orthop Res 14 (2): 316-323. (Pubitemid 26146005)
17. Quarto N, Longaker MT,. 2006. FGF-2 inhibits osteogenesis in mouse adipose tissue-derived stromal cells and sustains their proliferative and osteogenic potential state. Tissue Eng 12 (6): 1405-1418. (Pubitemid 44174777)
18. Ennett AB, Kaigler D, Mooney DJ,. 2006. Temporally regulated delivery of VEGF in vitro and in vivo. J Biomed Mater Res A 79 (1): 176-184. (Pubitemid 44452868)
19. Mayr-Wohlfart U, Waltenberger J, Hausser H, et al. 2002. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 30 (3): 472-477. (Pubitemid 34204121)
20. Kempen DH, Lu L, Zhu X, et al. 2004. Development of biodegradable poly(propylene fumarate)/poly(lactic-co-glycolic acid) blend microspheres. I. Preparation and characterization. J Biomed Mater Res A 70 (2): 283-292. (Pubitemid 38992325)
21. Kempen DH, Lu L, Zhu X, et al. 2004. Development of biodegradable poly(propylene fumarate)/poly(lactic-co-glycolic acid) blend microspheres. II. Controlled drug release and microsphere degradation. J Biomed Mater Res A 70 (2): 293-302. (Pubitemid 38988759)
22. Kempen DH, Lu L, Kim C, et al. 2006. Controlled drug release from a novel injectable biodegradable microsphere/scaffold composite based on poly(propylene fumarate). J Biomed Mater Res A 77 (1): 103-111.
23. King TW, Patrick CW Jr., 2000. Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D-L -lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique. J Biomed Mater Res 51 (3): 383-390. (Pubitemid 30452141)
24. Ohno T, Pelzer M, Larsen M, et al. 2007. Host-derived angiogenesis maintains bone blood flow after withdrawal of immunosuppression. Microsurgery 27 (8): 657-663. (Pubitemid 350175152)
25. Larsen M, Pelzer M, Friedrich PF, et al. 2008. Measurement of bone blood flow using the hydrogen washout technique-part II: validation by comparison to microsphere entrapment. J Orthop Res 26 (6): 746-752.
26. Pelzer M, Larsen M, Friedrich PF, et al. 2008. Measurement of bone blood flow using the hydrogen washout Technique-Part I: quantitative evaluation of tissue perfusion in the laboratory rat. J Orthop Res 26 (6): 741-745.
27. Spalteholz K,. 1914. Über das Durchsichtigmachen von menschlichen und tierischen Präparaten und seine theoretischen Bedingungen. Nebst Anhang: Über Knochenfärbung. Leipzig: S. Hirzel.
28. Parfitt AM, Drezner MK, Glorieux FH, et al. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2 (6): 595-610.
29. Guenther HL, Fleisch H, Sorgente N,. 1986. Endothelial cells in culture synthesize a potent bone cell active mitogen. Endocrinology 119 (1): 193-201. (Pubitemid 16100725)
30. Sakakibara Y, Tambara K, Sakaguchi G, et al. 2003. Toward surgical angiogenesis using slow-released basic fibroblast growth factor. Eur J Cardiothorac Surg 24 (1): 105-111; discussion 112.
31. Sato K, Laham RJ, Pearlman JD, et al. 2000. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thorac Surg 70 (6): 2113-2118. (Pubitemid 32015318)
32. Eckardt H, Ding M, Lind M, et al. 2005. Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. J Bone Joint Surg Br 87 (10): 1434-1438. (Pubitemid 41511813)
33. Eckardt H, Bundgaard KG, Christensen KS, et al. 2003. Effects of locally applied vascular endothelial growth factor (VEGF) and VEGF-inhibitor to the rabbit tibia during distraction osteogenesis. J Orthop Res 21 (2): 335-340. (Pubitemid 36322555)
34. Suzuki O, Bishop AT, Sunagawa T, et al. 2004. VEGF-promoted surgical angiogenesis in necrotic bone. Microsurgery 24 (1): 85-91. (Pubitemid 38174362)
35. Ito H, Koefoed M, Tiyapatanaputi P, et al. 2005. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med 11 (3): 291-297. (Pubitemid 40460557)
36. Katsube K, Bishop AT, Simari RD, et al. 2005. Vascular endothelial growth factor (VEGF) gene transfer enhances surgical revascularization of necrotic bone. J Orthop Res 23 (2): 469-474. (Pubitemid 40287877)
37. Huang Z, Ryu W, Ren P, et al. 2008. Controlled release of growth factors on allograft bone in vitro. Clin Orthop Relat Res 466 (8): 1905-1911.
38. Lamerigts NM, Buma P, Aspenberg P, et al. 1999. Role of growth factors in the incorporation of unloaded bone allografts in the goat. Clin Orthop Relat Res 368: 260-270. (Pubitemid 29534003)
39. Maus U, Andereya S, Ohnsorge JA, et al. 2008. A bFGF/TCP-composite inhibits bone formation in a sheep model. J Biomed Mater Res B Appl Biomater 85 (1): 87-92. (Pubitemid 351458231)
40. Montero A, Okada Y, Tomita M, et al. 2000. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 105 (8): 1085-1093. (Pubitemid 30217693)
41. Pepper MS, Ferrara N, Orci L, et al. 1992. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189 (2): 824-831. (Pubitemid 23032448)
42. Kumta S, Yip K, Roy N, et al. 1996. Revascularisation of bone allografts following vascular bundle implantation: an experimental study in rats. Arch Orthop Trauma Surg 115 (3-4): 206-210. (Pubitemid 26112495)